Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC)

An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period

The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical episode consistent with multiple sclerosis (MS) to clinically definite multiple sclerosis (CDMS).

The secondary objectives were:

• To demonstrate the effect of teriflunomide, in comparison to placebo, on:

  • Reducing conversion to definite multiple sclerosis (DMS)
  • Reducing annualized relapse rate (ARR)
  • Reducing disease activity/progression as measured by Magnetic Resonance Imaging (MRI)
  • Reducing accumulation of disability for at least 12 weeks as measured by the Expanded Disability Status Scale (EDSS)
  • Proportion of disability-free participants as assessed by the EDSS
  • Reducing participant-reported fatigue
• To evaluate the safety and tolerability of teriflunomide
• To evaluate the pharmacokinetics (PK) of teriflunomide
• Optional pharmacogenomic testing aimed at assessing the association between the main enzyme systems of teriflunomide metabolism and hepatic safety, and other potential associations between gene variations and clinical outcomes

Study Overview

• Status: Completed
• Conditions: Multiple Sclerosis
• Intervention / Treatment: Drug: Teriflunomide; Drug: Placebo

Detailed Description

The study consisted of 4 periods:

• Screening period: up to 4 weeks,
• Placebo-controlled treatment period: up to 108 weeks (at least 24 weeks for participants who experienced conversion to CDMS),
• Extension treatment period (without placebo-control): the extension period continued until teriflunomide was commercially available in participant's country of residence.
• Post-treatment washout period: 4 weeks after last treatment intake.

The maximal duration of the study period per participant was expected to be 116 weeks if he/she did not continue in the extension treatment period.

• Study Type: Interventional
• Enrollment (Actual): 618
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Geelong, Australia, 3220
    • Investigational Site Number 1405
  • Heidelberg, Australia, 3081
    • Investigational Site Number 1404
  • Hobart, Australia, 7001
    • Investigational Site Number 1407
  • Parkville, Australia, 3050
    • Investigational Site Number 1401
• Austria
  • Innsbruck, Austria, 6020
    • Investigational Site Number 4004
  • Linz, Austria, 4020
    • Investigational Site Number 4005
  • Wien, Austria, 1010
    • Investigational Site Number 4001
• Bulgaria
  • Pleven, Bulgaria, 5800
    • Investigational Site Number 5312
  • Sofia, Bulgaria, 1000
    • Investigational Site Number 5307
  • Sofia, Bulgaria, 1407
    • Investigational Site Number 5304
  • Sofia, Bulgaria, 1431
    • Investigational Site Number 5309
  • Sofia, Bulgaria, 1527
    • Investigational Site Number 5303
  • Sofia, Bulgaria, 1606
    • Investigational Site Number 5306
• Canada
  • Greenfield Park, Canada, J4V 2J2
    • Investigational Site Number 5402
  • London, Canada, N6A 5A5
    • Investigational Site Number 5403
  • Montreal, Canada, H1T 2M4
    • Investigational Site Number 5409
  • Ottawa, Canada, K1H 8L6
    • Investigational Site Number 5401
  • Quebec, Canada, G1J 1Z4
    • Investigational Site Number 5406
  • Sherbrooke, Canada, J1H 5N4
    • Investigational Site Number 5408
  • Toronto, Canada, M4N 3M5
    • Investigational Site Number 5410
  • Toronto, Canada, M5B 1W8
    • Investigational Site Number 5404
• Chile
  • Santiago, Chile, 760-0746
    • Investigational Site Number 5602
  • Santiago, Chile
    • Investigational Site Number 5601
  • Santiago, Chile
    • Investigational Site Number 5606
  • Viña Del Mar, Chile, 2520997
    • Investigational Site Number 5605
• Czech Republic
  • Brno, Czech Republic, 65691
    • Investigational Site Number 5801
  • Hradec Kralove, Czech Republic, 50005
    • Investigational Site Number 5803
  • Olomouc, Czech Republic, 77520
    • Investigational Site Number 5804
  • Ostrava - Poruba, Czech Republic, 70852
    • Investigational Site Number 5805
• Denmark
  • Aarhus C, Denmark, 8000
    • Investigational Site Number 6002
  • Esbjerg, Denmark, 6700
    • Investigational Site Number 6004
• Estonia
  • Tallinn, Estonia, 10617
    • Investigational Site Number 6201
  • Tartu, Estonia, 50406
    • Investigational Site Number 6203
• Finland
  • Helsinki, Finland, 00100
    • Investigational Site Number 6405
  • Kuopio, Finland, 70210
    • Investigational Site Number 6403
  • Turku, Finland, 20100
    • Investigational Site Number 6401
• France
  • Besancon, France, 25030
    • Investigational Site Number 6611
  • Clermont Ferrand Cedex 1, France, 63003
    • Investigational Site Number 6601
  • Lille Cedex, France, 59037
    • Investigational Site Number 6609
  • Montpellier Cedex 05, France, 34295
    • Investigational Site Number 6604
  • Nancy Cedex, France, 54036
    • Investigational Site Number 6612
  • Nantes Cedex 01, France, 44093
    • Investigational Site Number 6605
  • Nice Cedex, France, 06002
    • Investigational Site Number 6602
  • Nimes, France, 30029
    • Investigational Site Number 6614
  • Strasbourg Cedex, France, 67091
    • Investigational Site Number 6607
• Germany
  • Bayreuth, Germany, 95445
    • Investigational Site Number 6801
  • Berlin, Germany, 10713
    • Investigational Site Number 6810
  • Berlin, Germany, 10785
    • Investigational Site Number 6805
  • Erbach, Germany, 64711
    • Investigational Site Number 6807
  • Essen, Germany, 45122
    • Investigational Site Number 6803
  • Hannover, Germany, 30625
    • Investigational Site Number 6809
  • Ludwigshafen, Germany, 67063
    • Investigational Site Number 6804
  • Minden, Germany, 32429
    • Investigational Site Number 6815
  • Münster, Germany, 48149
    • Investigational Site Number 6802
  • Wiesbaden, Germany, 65191
    • Investigational Site Number 6806
• Hungary
  • Budapest, Hungary, 1076
    • Investigational Site Number 7101
  • Budapest, Hungary, 1145
    • Investigational Site Number 7103
  • Esztergom, Hungary, 2500
    • Investigational Site Number 7108
  • Veszprém, Hungary, 8200
    • Investigational Site Number 7105
• Lithuania
  • Klaipeda, Lithuania, LT-92288
    • Investigational Site Number 7402
  • Siauliai, Lithuania, LT-76231
    • Investigational Site Number 7403
  • Vilnius, Lithuania, LT-08661
    • Investigational Site Number 7401
• Mexico
  • Chihuahua, Mexico, 31203
    • Investigational Site Number 7501
  • Guadalajara, Mexico, 45110
    • Investigational Site Number 7502
• Poland
  • Gdansk, Poland, 80-803
    • Investigational Site Number 7709
  • Lodz, Poland, 93-513
    • Investigational Site Number 7710
  • Warszawa, Poland, 02-097
    • Investigational Site Number 7701
  • Warszawa, Poland, 02-957
    • Investigational Site Number 7703
  • Warszawa 44, Poland, 04-141
    • Investigational Site Number 7707
• Romania
  • Bucuresti, Romania, 020125
    • Investigational Site Number 7803
  • Bucuresti, Romania, 050098
    • Investigational Site Number 7806
  • Cluj-Napoca, Romania, 400012
    • Investigational Site Number 7805
  • Cluj-Napoca, Romania, 400012
    • Investigational Site Number 7807
  • Timisoara, Romania, 300736
    • Investigational Site Number 7808
• Russian Federation
  • Kazan, Russian Federation, 420021
    • Investigational Site Number 7907
  • Nizhny Novgorod, Russian Federation, 603000
    • Investigational Site Number 7909
  • Nizhny Novgorod, Russian Federation, 603076
    • Investigational Site Number 7906
  • Nizhny Novgorod, Russian Federation, 603126
    • Investigational Site Number 7904
  • Novosibirsk, Russian Federation, 630007
    • Investigational Site Number 7912
  • Rostov-On-Don, Russian Federation, 344085
    • Investigational Site Number 7910
  • Smolensk, Russian Federation, 214019
    • Investigational Site Number 7905
  • St-Petersburg, Russian Federation, 194044
    • Investigational Site Number 7911
• Turkey
  • Edirne, Turkey
    • Investigational Site Number 8304
  • Istanbul, Turkey, 34390
    • Investigational Site Number 8309
  • Istanbul, Turkey, 34400
    • Investigational Site Number 8315
  • Istanbul, Turkey
    • Investigational Site Number 8308
  • Istanbul, Turkey
    • Investigational Site Number 8310
  • Istanbul, Turkey
    • Investigational Site Number 8312
  • Izmir, Turkey, 35100
    • Investigational Site Number 8305
  • Izmir, Turkey, 35340
    • Investigational Site Number 8301
  • Izmir, Turkey, 35380
    • Investigational Site Number 8303
  • Izmit, Turkey, 41380
    • Investigational Site Number 8302
  • Trabzon, Turkey, 61080
    • Investigational Site Number 8314
• Ukraine
  • Chernihiv, Ukraine, 14029
    • Investigational Site Number 8507
  • Dnipropetrovsk, Ukraine, 49027
    • Investigational Site Number 8501
  • Donets'K, Ukraine, 83099
    • Investigational Site Number 8511
  • Kharkiv, Ukraine, 61018
    • Investigational Site Number 8506
  • Kharkiv, Ukraine, 61178
    • Investigational Site Number 8504
  • Kiev, Ukraine, 03110
    • Investigational Site Number 8508
  • Lutsk, Ukraine, 43005
    • Investigational Site Number 8512
  • Lviv, Ukraine, 79010
    • Investigational Site Number 8505
  • Poltava, Ukraine, 36011
    • Investigational Site Number 8510
  • Vinnytsya, Ukraine, 21005
    • Investigational Site Number 8503
  • Zaporizhzhya, Ukraine, 69000
    • Investigational Site Number 8502
• United Kingdom
  • Liverpool, United Kingdom, L9 7LJ
    • Investigational Site Number 8709
  • London, United Kingdom, E1 1BB
    • Investigational Site Number 8701
  • London, United Kingdom, SW17 0QT
    • Investigational Site Number 8704
  • Newcastle Upon Tyne, United Kingdom, NE1 4LP
    • Investigational Site Number 8706
  • Nottingham, United Kingdom, NG7 2UH
    • Investigational Site Number 8705
  • Plymouth, United Kingdom, PL6 5BX
    • Investigational Site Number 8708
  • Salford, United Kingdom, M6 8HD
    • Investigational Site Number 8707
  • Sheffield, United Kingdom, S10 2JF
    • Investigational Site Number 8702
• United States
  • Alabama
    • Cullman, Alabama, United States, 35058
      • Investigational Site Number 8965
  • Arizona
    • Phoenix, Arizona, United States, 85013-4496
      • Investigational Site Number 8954
    • Phoenix, Arizona, United States, 85060
      • Investigational Site Number 8946
  • Colorado
    • Fort Collins, Colorado, United States, 80528
      • Investigational Site Number 8962
  • Florida
    • Maitland, Florida, United States, 32761
      • Investigational Site Number 8920
    • St. Petersburg, Florida, United States, 33701
      • Investigational Site Number 8953
  • Indiana
    • Ft. Wayne, Indiana, United States, 63104
      • Investigational Site Number 8914
    • Indianapolis, Indiana, United States, 46256
      • Investigational Site Number 8940
  • Louisiana
    • Shreveport, Louisiana, United States, 71103
      • Investigational Site Number 8922
  • Michigan
    • Grand Rapids, Michigan, United States, 49503
      • Investigational Site Number 8955
    • Traverse City, Michigan, United States, 49684
      • Investigational Site Number 8949
  • Missouri
    • St Louis, Missouri, United States, 63104
      • Investigational Site Number 8937
  • New Mexico
    • Albuquerque, New Mexico, United States, 87131
      • Investigational Site Number 8951
  • New York
    • New York, New York, United States, 10029-6574
      • Investigational Site Number 8925
  • North Carolina
    • Charlotte, North Carolina, United States, 28204
      • Investigational Site Number 8941
  • Ohio
    • Dayton, Ohio, United States, 45409
      • Investigational Site Number 8924
  • Tennessee
    • Round Rock, Tennessee, United States, 78681
      • Investigational Site Number 8905
  • Vermont
    • Burlington, Vermont, United States, 05401
      • Investigational Site Number 8930
  • Washington
    • Seattle, Washington, United States, 98122
      • Investigational Site Number 8963

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• First acute or subacute, well-defined neurological event consistent with demyelination (that is, optic neuritis confirmed by an ophthalmologist, spinal cord syndrome, brainstem/cerebellar syndromes)
• Onset of MS symptoms occurring within 90 days of randomization
• A screening MRI scan with 2 or more T2 lesions at least 3 millimeter (mm) in diameter that are characteristic of MS

Exclusion Criteria:

• Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease
• Significantly impaired bone marrow function
• Pregnancy or nursing
• Alcohol or drug abuse
• Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment
• Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg; Core treatment period: Placebo matched to teriflunomide tablet once daily orally. Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally.	Drug: Teriflunomide; Film-coated tablet Oral administration; Other Names: Aubagio; HMR1726; Drug: Placebo; Film-coated tablet Oral administration
Experimental: Teriflunomide 7 mg/7 mg; Core treatment period: Teriflunomide 7 mg tablet once daily orally. Extension treatment period: Teriflunomide 7 mg tablet once daily orally.	Drug: Teriflunomide; Film-coated tablet Oral administration; Other Names: Aubagio; HMR1726
Experimental: Teriflunomide 14 mg/14 mg; Core treatment period: Teriflunomide 14 mg tablet once daily orally. Extension treatment period: Teriflunomide 14 mg tablet once daily orally.	Drug: Teriflunomide; Film-coated tablet Oral administration; Other Names: Aubagio; HMR1726

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Core Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS)	Conversion to CDMS was defined by the occurrence of a relapse, which was defined as a new neurological abnormality separated by at least 30 days from onset of a preceding clinical event, presented for at least 24 hours and occurred in the absence of fever or known infection. Percent probability of conversion at 24, 48, and 108 weeks was estimated using Kaplan-Meier method.	Up to a maximum of 108 weeks depending on time of enrollment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Core Treatment Period: Time to Conversion to Definite Multiple Sclerosis (DMS)	Conversion to DMS was demonstrated by dissemination of MRI lesions in time (as per McDonald criteria) or a relapse, whichever occurs first. MRI Imaging criteria were detection of Gadolinium (Gd) enhancement at least 3 months after onset of initial clinical event, if not at site corresponding to initial event; detection of new T2 lesion if it appears at any time compared with reference scan (done at time of screening) done at least 30 days after onset of the initial clinical event. Occurrence of relapse was defined as new neurological abnormality separated by at least 30 days from onset of preceding clinical event, present for at least 24 hours and occurring in absence of fever or known infection. New clinical abnormality (neurological sign) that is consistent with participant's symptoms with increase in at least one Functional System (FS) or EDSS score compared to last EDSS assessment. Percent probability of conversion at 24, 48, and 108 weeks was estimated using Kaplan-Meier method.	Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Annualized Relapse Rate (ARR)	ARR is the total number of confirmed relapses that occurred during the treatment period divided by the total number of patient-years treated. Each episode of relapse (appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever) was to be confirmed by an increase in EDSS score or Functional System scores. ARR was assessed using Poisson regression model with robust error variance. To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses onset between randomization date and last dose date as the response variable, treatment, region and baseline monofocal/multifocal status as covariates, and log-transformed treatment duration as an offset variable).	Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Brain Magnetic Resonance Imaging (MRI) Assessment: Change From Baseline in Total Lesion Volume at Week 108	The total lesion volume (burden of disease) is the total volumes of hyperintense on T2 plus hypointense on T1 as measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data with factors for treatment, baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, cubic root transformed baseline burden of disease, and baseline-by-visit interaction.	Baseline, Week 108
Core Treatment Period: Brain MRI Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per MRI Scan (Poisson Regression Estimates)	Number of Gd-enhancing T1-lesions per scan is the total number of Gd-enhancing T1-lesions that occurred during the treatment period divided by the total number of scans performed during the treatment period. To account for the different numbers of scans performed among the participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable, treatment, baseline monofocal/multifocal status, region and baseline number of Gd-enhancing T1-lesions as covariates, and log-transformed number of scans as an offset variable).	Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Brain MRI Assessment: Volume of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per MRI Scan	Total volume of Gd-enhancing T1-lesions per scan is the sum of the volumes of Gd-enhancing T1-lesions observed during the treatment period divided by the total number of scans performed during the treatment period. To account for the different numbers of scans performed among the participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable, treatment, baseline monofocal/multifocal status, region and baseline number of Gd-enhancing T1-lesions as covariates, and log-transformed number of scans as an offset variable).	Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Brain MRI Assessment: Change From Baseline in Volume of Hypointense Post-Gadolinium T1 Lesion Component	Volume of hypointense post-gadolinium T1 lesion component was measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data adjusted for baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, cubic root transformed baseline value, and baseline-by-visit interaction	Baseline, Week 108
Core Treatment Period: Brain MRI Assessment: Change From Baseline in Volume of T2 Lesion Component	Volume of T2 lesion component was measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data adjusted for baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, cubic root transformed baseline value, and baseline-by-visit interaction.	Baseline, Week 108
Core Treatment Period: Brain MRI Assessment: Percent Change From Baseline in Atrophy	Atrophy was measured by MRI scan.	Baseline, Week 108
Core Treatment Period: Time to 12-Week Sustained Disability Progression	The 12-week sustained disability progression was defined as increase from baseline of at least 1-point in EDSS score (at least 0.5-point for participants with baseline EDSS score of greater than [>] 5.5) that persisted for at least 12 weeks. Percent probability of participants free of 12-week sustained disability progression at 24, 48, and 108 weeks was estimated using Kaplan-Meier method.	Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Change From Baseline in EDSS at Week 108	EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS). Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data adjusted for baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, baseline value and baseline-by-visit interaction	Baseline, Week 108
Core Treatment Period: Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 108	FIS is a participant-reported scale that qualifies the impact of fatigue on daily life in participants with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social. FIS total score ranges from 0 (no problem) to 160 (extreme problem). Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on FIS total score data adjusted for or baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, baseline value and baseline-by-visit interaction.	Baseline, Week 108
Core Treatment Period: Overview of Adverse Events (AEs)	AEs are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.	From first study drug intake up to 112 days after last intake in the placebo-controlled period or up to first intake in the extension treatment period, whichever occurred first
Extension Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS)	Conversion to CDMS was defined by the occurrence of a relapse, which was defined as a new neurological abnormality separated by at least 30 days from onset of a preceding clinical event, presented for at least 24 hours and occurred in the absence of fever or known infection. Percent probability of conversion was estimated using Kaplan-Meier method.	From randomization in the core period up to 390 Weeks (Extension treatment period [maximum exposure: 283 Weeks])
Extension Treatment Period: Overview of Adverse Events (AEs)	AEs are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. Safety population included all randomized population who actually received at least 1 dose of the IMP in extension and analyzed according to the treatment actually received in core study followed by treatment actually received in the extension treatment period.	From re-randomization up to 283 Weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Core Treatment Period: Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)	PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review. Hepatic parameters thresholds were defined as follows: Alanine Aminotransferase (ALT) >3, 5, 10 or 20 upper limit of normal(ULN);; Aspartate aminotransferase (AST) >3, 5, 10 or 20 ULN;; Alkaline Phosphatase >1.5 ULN;; Total Bilirubin (TB) >1.5, 2, or 3 ULN;; ALT >3 ULN and TB >2 ULN.	From first study drug intake up to 112 days after last intake in the placebo-controlled period or up to first intake in the extension treatment period, whichever occurred first

Collaborators and Investigators

• Sponsor: Sanofi

Publications and helpful links

General Publications

• Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Oct;13(10):977-86. doi: 10.1016/S1474-4422(14)70191-7. Epub 2014 Sep 2.

Study record dates

Study Major Dates

• Study Start: February 1, 2008
• Primary Completion (Actual): December 1, 2012
• Study Completion (Actual): February 1, 2016

Study Registration Dates

• First Submitted: February 14, 2008
• First Submitted That Met QC Criteria: February 22, 2008
• First Posted (Estimate): February 25, 2008

Study Record Updates

• Last Update Posted (Actual): March 13, 2017
• Last Update Submitted That Met QC Criteria: January 20, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: MS; CIS; Clinically Isolated Syndrome; relapses; CDMS
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Multiple Sclerosis; Sclerosis; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Immunosuppressive Agents; Immunologic Factors; Teriflunomide
• Other Study ID Numbers: EFC6260; HMR1726D-3005 (Other Identifier: HMR); 2006-001152-12 (EudraCT Number)